Bièche I, Olivi M, Champème M H, Vidaud D, Lidereau R, Vidaud M
Laboratoire de Génétique Moléculaire, Faculté des Sciences Pharmaceutiques et Biologiques de Paris, France.
Int J Cancer. 1998 Nov 23;78(5):661-6. doi: 10.1002/(sici)1097-0215(19981123)78:5<661::aid-ijc22>3.0.co;2-i.
Gene amplification is a common event in the progression of human cancers, and amplified oncogenes have been shown to have diagnostic, prognostic and therapeutic relevance. A kinetic quantitative polymerase-chain-reaction (PCR) method, based on fluorescent TaqMan methodology and a new instrument (ABI Prism 7700 Sequence Detection System) capable of measuring fluorescence in real-time, was used to quantify gene amplification in tumor DNA. Reactions are characterized by the point during cycling when PCR amplification is still in the exponential phase, rather than the amount of PCR product accumulated after a fixed number of cycles. None of the reaction components is limited during the exponential phase, meaning that values are highly reproducible in reactions starting with the same copy number. This greatly improves the precision of DNA quantification. Moreover, real-time PCR does not require post-PCR sample handling, thereby preventing potential PCR-product carry-over contamination; it possesses a wide dynamic range of quantification and results in much faster and higher sample throughput. The real-time PCR method, was used to develop and validate a simple and rapid assay for the detection and quantification of the 3 most frequently amplified genes (myc, ccndl and erbB2) in breast tumors. Extra copies of myc, ccndl and erbB2 were observed in 10, 23 and 15%, respectively, of 108 breast-tumor DNA; the largest observed numbers of gene copies were 4.6, 18.6 and 15.1, respectively. These results correlated well with those of Southern blotting. The use of this new semi-automated technique will make molecular analysis of human cancers simpler and more reliable, and should find broad applications in clinical and research settings.
基因扩增是人类癌症进展过程中的常见事件,已证明扩增的癌基因具有诊断、预后和治疗意义。一种基于荧光TaqMan方法和能够实时测量荧光的新型仪器(ABI Prism 7700序列检测系统)的动力学定量聚合酶链反应(PCR)方法,被用于定量肿瘤DNA中的基因扩增。反应的特征在于循环过程中PCR扩增仍处于指数期的时间点,而不是固定循环次数后积累的PCR产物量。在指数期,反应成分均不受限制,这意味着从相同拷贝数开始的反应中,数值具有高度可重复性。这大大提高了DNA定量的精度。此外,实时PCR不需要PCR后样本处理,从而防止了潜在的PCR产物污染;它具有广泛的定量动态范围,并且能实现更快、更高的样本通量。实时PCR方法被用于开发和验证一种简单快速的检测方法,用于检测和定量乳腺肿瘤中3种最常扩增的基因(myc、ccndl和erbB2)。在108份乳腺肿瘤DNA中,分别有10%、23%和15%观察到myc、ccndl和erbB2的额外拷贝;观察到的最大基因拷贝数分别为4.6、18.6和15.1。这些结果与Southern印迹法的结果相关性良好。这种新的半自动技术的应用将使人类癌症的分子分析更简单、更可靠,并应在临床和研究环境中得到广泛应用。